Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engineering Immune Organoids to Study Pediatric Cancer
NCT05890781Recruiting
- Sponsor
- Gustave Roussy
- Start
- May 2023
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Single-arm trial, sponsored by Gustave Roussy. Primary endpoint: Proportion of viable and exploitable immune organoids with engrafted tumor cells at 5 years. Started May 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05890781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890781.